XNASXERS
Market cap500mUSD
Jan 08, Last price
3.36USD
1D
0.30%
1Q
20.86%
IPO
-82.13%
Name
Xeris Biopharma Holdings Inc
Chart & Performance
P/E
—
P/S
3.06
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
62.78%
Rev. gr., 5y
131.50%
Revenues
164m
+48.68%
Net income
-62m
L-34.23%
CFO
-47m
L-54.30%
Earnings
Mar 04, 2025
Profile
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 163,914 48.68% | 110,248 0.00% | ||||||
Cost of revenue | 50,986 | 43,600 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 112,928 | 66,648 | ||||||
NOPBT Margin | 68.89% | 60.45% | ||||||
Operating Taxes | (1,249) | (1,424) | ||||||
Tax Rate | ||||||||
NOPAT | 114,177 | 68,072 | ||||||
Net income | (62,255) -34.23% | (94,660) 0.00% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (1,009) | 29,532 | ||||||
BB yield | 0.31% | -16.37% | ||||||
| Debt | ||||||||
Debt current | 6,990 | 3,160 | ||||||
Long-term debt | 263,955 | 207,459 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 6,227 | 25,719 | ||||||
Net debt | 198,494 | 84,305 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (47,023) | (102,891) | ||||||
CAPEX | (2,263) | (524) | ||||||
Cash from investing activities | (6,004) | 34,461 | ||||||
Cash from financing activities | (1,613) | 127,473 | ||||||
FCF | 113,377 | 68,072 | ||||||
| Balance | ||||||||
Cash | 72,451 | 121,966 | ||||||
Long term investments | 4,348 | |||||||
Excess cash | 64,255 | 120,802 | ||||||
Stockholders' equity | (617,036) | (554,779) | ||||||
Invested Capital | 849,167 | 760,545 | ||||||
ROIC | 14.19% | 8.59% | ||||||
ROCE | 48.18% | 31.85% | ||||||
| EV | ||||||||
Common stock shares outstanding | 137,675 | 135,629 | ||||||
Price | 2.35 76.69% | 1.33 -54.61% | ||||||
Market cap | 323,536 79.36% | 180,386 -22.10% | ||||||
EV | 522,030 | 264,691 | ||||||
EBITDA | 126,088 | 79,316 | ||||||
EV/EBITDA | 4.14 | 3.34 | ||||||
Interest | 26,609 | 15,325 | ||||||
Interest/NOPBT | 23.56% | 22.99% | ||||||